Navigation Links
Anemia Drugs May Speed Tumor Growth in Some Cancer Patients

Widely prescribed blood-boosters might stimulate malignant cells, hasten death, study says

SUNDAY, June 1 (HealthDay News) -- Drugs used widely to treat anemia in cancer patients may actually speed progression of the cancer in certain individuals, but researchers report they may found a way to determine who those individuals are.

"We may have a test to predict whether a patient is susceptible to having their tumor progress if treated with erythropoietin and, alternatively, we may be able to predict patients it would be safe to treat with erythropoietin," study author Dr. Tony Blau, of the University of Washington in Seattle, said during a Sunday news conference at the American Society of Clinical Oncology annual meeting in Chicago.

Recent controversy over erythropoiesis-stimulating agents (ESAs) such as Procrit, Epogen and Aranesp has centered around whether the blood-boosting drugs should be withdrawn from the market because of troubling side effects.

In March, a U.S. Food and Drug Administration advisory panel voted to recommend continued use of the drugs for patients on chemotherapy, unless the patient is likely to be cured. They also voted to recommend against the drugs' use in patients with breast or head and neck cancer.

Eight clinical trials now suggest these medications actually speed the growth of tumors and shorten the lives of cancer victims.

The drugs' manufacturers added a "black box" warning to the medications last November.

"There has been lots of controversy over these stimulating agents, and we have an FDA advisory committee to act on this as we speak," said Dr. Julie Gralow, director of breast oncology at the University of Washington and Fred Hutchinson Cancer Center in Seattle and moderator of the Sunday news conference. "The drugs offer benefits in terms of reducing anemia and reducing transfusions, but several large trials in a variety of tumor types suggest that . . . these agents may have some stimulatory effects on tumor cells, faster progression in some cases, and more death in others."

Until recently, Blau added, these drugs represented the biggest U.S. federal expenditures for oncology patients.

The results of the current study were based on analyses of tumor samples from 101 patients diagnosed with head and neck cancer who had participated in a previous phase III trial of erythropoietin.

Scientists measured levels of erythropoietin receptor (EpoR) messenger RNA (mRNA).

High levels of EpoR mRNA in patients who had undergone radiation but not surgery tended to signal a worse prognosis. There was a similar effect with Janus Kinase 2 (Jak2), the main intermediary of EpoR signaling, Blau added.

"These are preliminary findings, but they're very exciting," Gralow said. "If they hold up, they may mean that we may be able to use ESAs in targeted ways."

"These findings must be considered preliminary until confirmed," added Blau. "We believe that the definitive answer to this question lies locked in the filing cabinets of pathologists' offices that contain tumors of patients who participated in already completed phase III studies." That, of course, would be much easier than initiating entirely new studies.

A second study found the multiple drugs elderly cancer patients may already be taking could interact significantly with chemotherapy.

In particular, patients taking drugs that interfered with protein binding such as Norvasc for high blood pressure, Prilosec for heartburn, and the pain reliever Celebrex were more likely to experience hematologic side effects such as low white blood cell counts.

Patients taking drugs that act on a group of enzymes known as cytochrome p450 were more likely to experience effects such as fatigue or diarrhea. Examples of these drugs include the heart medications such as Pacerone and Cordarone.

"We found that all drugs patients are taking besides chemotherapy are likely to affect their tolerance to chemotherapy," said study author Dr. Mihaela Popa, of the H. Lee Moffitt Cancer Center in Tampa, Fla.

More information

The American Cancer Society has more on cancer-related fatigue and anemia.

SOURCES: June 1, 2008, news conference with Tony Blau, M.D., associate professor, medicine, division of hematology, University of Washington, Seattle; Julie Gralow, M.D., director, breast oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle; and Mihaela Popa, M.D., Ph.D., H. Lee Moffitt Cancer Center, Tampa, Fla.; June 1, 2008, presentation, American Society for Clinical Oncology, Chicago

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
2. Twin findings raise hopes of improved anemia treatments
3. Anemia Triples Risk of Local Recurrence in Breast Cancer Patients
4. FDA Panel Supports Anemia Drugs for Cancer Patients
5. FDA Panel Weighs Safety of Anemia Drugs for Cancer Patients
6. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
7. Drugs used for cancer-associated anemia linked with increased risk of blood clots, death
8. Anemia Drugs for Cancer Patients Increase Death Risk
9. Anemia treatment may be a double-edged sword
10. FDA Reports New Risks Posed by Anemia Drugs
11. Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia
Post Your Comments:
(Date:10/12/2015)... Grove Village, IL, USA (PRWEB) , ... October ... ... solutions and high-fidelity personal audio products, will present the latest version of Companion ... insert earphones for audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) ...
(Date:10/12/2015)... ... October 12, 2015 , ... FEI Behavioral Health, ... from EAP to crisis management, will present a session at the Wisconsin Society ... 14-16, 2015. , FEI’s Chief Operating Officer Daniel Potterton will present an informative ...
(Date:10/12/2015)... FL (PRWEB) , ... October 12, 2015 , ... ... Awareness Month, IQ Formulations today announced its charitable donation to the National Breast ... inspiring hope in those affected by breast cancer through early detection, education, and ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group is proud ... contact channel benchmarking study. Be a part of this insightful and leading-edge ... customer experience, customer journey, contact channel execution and intelligence, workforce optimization, and tools ...
(Date:10/12/2015)... ... October 12, 2015 , ... Holcomb – Kreithen Plastic ... in Florida, announced today that it will host “Plastic Surgery University,” an educational series ... Town Center (“UTC Mall”) in Sarasota, FL on Saturday, October 24, 2015. , ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Leadership of the National Association of Vision Care ... Aspasia Shappet , CEO of MESVision resumed her role as ... at its annual strategic planning meeting in Chicago ... the organization from May 2013 to May of this year. ... a result of the increased demands of his recent appointment ...
(Date:10/12/2015)... , Oct. 12, 2015 A new computer ... children can predict whether they will develop effective language ... to a study in the journal Brain and ... --> In the journal,s Oct. 12 online edition, ... computer program determines how specific regions of the brain ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
Breaking Medicine Technology: